Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Stock analysts at Jefferies Group issued their Q3 2017 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a research note issued on Thursday. Jefferies Group …
Why were investors so anxious to snatch up VNDA stock? Well, Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. …
If you check you will find that VNDA stock has a topline or revenue of $42.06M for 2017-Q2 as per this Vanda Pharmaceuticals revenue chart. Investors look for stocks with a growing top line. Bottom line: The Bottomline or the net …
JMP Securities increased Vanda Pharma's (VNDA) stock price target to $22 from $18 after a judge ruled that a generic drug maker's medication violated the company's patents. A Delaware court ruled Thursday that Roxane Laboratories …
After a surprise FDA approval for Fanapt (iloperidone) for second-line schizophrenia therapy in May 2009, Vanda Pharmaceuticals (NASDAQ:VNDA) stock rose nearly 800% and has traded in the $12-$15 range since then until mid …
Vanda Pharmaceuticals Inc. (VNDA) stock volume is at a 52-week peak, while options are crossing at eight times the average pace More broadly speaking, traders are more call-heavy than usual among options set to expire in three …
If you want a Stock Review on CRIS, OVAS, RGLS or VNDA then come over to http://dailystocktracker.com/register …
Did TIAA-CREF sell VNDA from some of the questionable portfolios? Yes. Let me tell you a story. I want to tell you a story about an underperforming stock in an inappropriate pension fund, a few resignations, and how the stock is no longer in …
I read this article and found it very interesting, thought it might be interesting for you. The article is called Will H.C. …